Chronic care platforms are consolidating faster than anyone predicted

From single-condition to multi-condition

The single-condition digital therapeutic that raised at a billion-dollar valuation in 2021 has largely failed to scale. Payers do not want to procure eight different vendors for eight overlapping populations. The winners are becoming multi-condition operators.

The M&A window is open

Well-capitalized platforms are acquiring point solutions at pennies on the dollar. Founders raising bridge rounds today should be honest about whether they are building a company or preparing an asset sale.

What payers actually buy

A single vendor, a single contract, a shared outcomes framework, and a single integration into utilization management. That is the winning package. Everything else is friction.

The clinical operating model

The horizontal platforms that will endure are the ones that own the clinical operating model — care teams, protocols, escalation — not just the software layer. Software-only players are being commoditized.

The economics of a shared care team

The unit economics driving consolidation are less about brand and more about staffing leverage. A nurse or health coach trained to manage diabetes can, with the right protocols, extend into hypertension and weight management without a proportional increase in headcount. Standalone single-condition companies structurally cannot capture that leverage, which puts them at a permanent cost disadvantage once a multi-condition competitor reaches scale in the same population.

We have watched founders discover this the hard way: a strong single-condition product with excellent retention still loses on gross margin to a platform that amortizes clinical staff, care coordination software, and biometric device logistics across several conditions at once. The lesson is not that single-condition companies are doomed, but that their path to durable margins increasingly runs through acquisition rather than independent scale.

An illustrative rollup

Consider a hypothetical operator that started in diabetes management, built a competent remote monitoring and coaching workflow, and then acquired two smaller companies — one in musculoskeletal care, one in behavioral health — rather than build those capabilities natively. Within a year the combined entity could offer a single enrollment pathway and a single care team model to an employer client, replacing what had been three separate vendor contracts and onboarding flows.

The acquired teams' technology was often less important than their clinical protocols and payer contracts, which is a pattern worth internalizing: buyers in this wave are paying for regulatory relationships, coded billing pathways, and trained clinical staff far more than for proprietary software.

The counterargument for staying focused

Not every founder should chase breadth. A company with genuinely superior outcomes in one high-cost condition — say, a specialty population with complex comorbidities — can still command premium pricing and licensing deals with horizontal platforms rather than needing to become one itself. Depth remains a viable strategy for teams willing to be acquired or embedded rather than to stay independent and general.

The risk of premature breadth is real: stretching a clinical team across conditions it does not understand well can erode the outcomes data that justified the premium pricing in the first place. Consolidation only works if the acquiring platform preserves clinical quality in each vertical, and several rollups have stumbled specifically because they treated protocols as interchangeable.

What this means for a founder today

If you are building a single-condition company now, treat your clinical protocol and payer contracting relationships as the asset you are actually building, not just your app. Those are the components that transfer cleanly into a larger platform and that determine your negotiating position in an acquisition conversation.

If you are building the platform, resist the temptation to integrate acquired teams too quickly. The operator discipline required to run five clinical protocols well is different from running one, and the consolidators that win this cycle will be the ones that scaled care operations as carefully as they scaled sales.